NeurAxis, Inc.

Contributing Author

Recent Articles by NeurAxis, Inc.

4 hours	NeurAxis Announces New Medical Policy Coverage with Two Health Insurers, Adding 700,000 Covered Lives NRXS GlobeNewswire
Jun-10	NeurAxis Achieves Critical Milestone; Secures Key Academic Society Guidelines Recommendation for Treatment of Functional Abdominal Pain (FAP) in IBS NRXS GlobeNewswire
May-27	NeurAxis to Participate in the Lytham Partners Spring 2025 Investor Conference on May 29, 2025 NRXS GlobeNewswire
May-22	NeurAxis Announces Closing of $5.0 Million Registered Direct Offering NRXS GlobeNewswire
May-21	NeurAxis Announces $5.0 Million Registered Direct Offering NRXS GlobeNewswire
May-20	NeurAxis Awarded First Ever FDA Clearance for the Treatment of Pediatric FAP/Functional Dyspepsia (FD) and Associated Nausea Symptoms NRXS GlobeNewswire
May-12	NeurAxis Reports Strong First Quarter 2025 Financial Results Driven by a 39% Growth in Revenues NRXS GlobeNewswire
May-05	NeurAxis to Host First Quarter 2025 Results and Business Update Call on Monday, May 12, 2025 NRXS GlobeNewswire